

**Supplementary Table 1.** Eligibility criteria of the three studied CVOTs completed for SGLT2i in T2D patients.

	EMPA-REG OUTCOME (empagliflozin / placebo)	CANVAS (canagliflozin / placebo)	DECLARE-TIMI 58 (dapagliflozin / placebo)
<b>Age</b>	≥18 years	<ul style="list-style-type: none"> <li>• ≥30 years in SP</li> <li>• ≥50 years in PP</li> </ul>	<ul style="list-style-type: none"> <li>• ≥40 years in SP</li> <li>• ≥55 years (≥60 in women) in PP</li> </ul>
<b>HbA1c</b>	<ul style="list-style-type: none"> <li>• If no glucose-lowering agents: 7.0%-9.0%</li> <li>• If glucose-lowering agents: 7.0%-10.0%</li> </ul>	≥7.0% - ≤10.5%	6.5%-12.0%
<b>Main inclusion criteria</b>	<p><u>Established CVD:</u></p> <ul style="list-style-type: none"> <li>• Myocardial infarction</li> <li>• CAD</li> <li>• Unstable angina</li> <li>• Stroke</li> <li>• PAD</li> </ul>	<p><u>≥30 years with established CVD (SP):</u></p> <ul style="list-style-type: none"> <li>• Ischaemic heart disease</li> <li>• Myocardial infarction</li> <li>• Unstable angina</li> <li>• Significant carotid or PAD</li> </ul> <p><u>≥50 years with high risk of CVD: ≥2 CV risk factors (PP):</u></p> <ul style="list-style-type: none"> <li>• ≥10 years T2D duration</li> <li>• Hypertension*</li> <li>• Current smoker</li> <li>• Micro or Macroalbuminuria</li> <li>• HDL-c &lt;39 mg/dl (&lt;1 mmol/l)</li> </ul>	<p><u>≥40 years with established CVD (SP):</u></p> <ul style="list-style-type: none"> <li>• Ischaemic heart disease</li> <li>• Cerebrovascular disease</li> <li>• PAD</li> </ul> <p><u>High risk of CVD; ≥2 CV risk factors (PP):</u></p> <ul style="list-style-type: none"> <li>• <b>Age AND</b> at least 1 of: <ul style="list-style-type: none"> <li>• Dyslipidemia**</li> <li>• Hypertension†</li> <li>• Current tobacco use</li> </ul> </li> </ul>
<b>Main exclusion criteria</b>	eGFR <30 ml/min/1.73 m <sup>2</sup>	eGFR <30 ml/min/1.73 m <sup>2</sup>	eGFR <60 ml/min/1.73 m <sup>2</sup>
	BMI ≥45 kg/m <sup>2</sup>		

CAD, coronary artery disease; CVD, cardiovascular disease; eGFR, estimated glomerular fraction; HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein-cholesterol; PAD, peripheral artery disease; PP, primary prevention; SP, secondary prevention; T2D, type 2 diabetes

\*Systolic pressure >140 mmHg while on ≥1 hypertensive agents

\*\*low-density lipoprotein-cholesterol (LDL-c) ≥130 mg/dl or use of lipid-lowering therapies

†Blood pressure >140/90 mmHg or on anti-hypertensive therapy

**Supplementary Table 2.** ICD-10 codes for cardiovascular diseases considered in the study.

Condition	ICD-10 codes
Acute myocardial infarction (<28 days)	I21
Old myocardial infarction	I25.2
Angor pectoris	I20.8
Unstable angina	I20.0
Coronary artery disease	I20-I25
Stroke	I61, I62.x (except: I62.9), I63, I64, I65.x, I67, I69, G45, and G46
Peripheral artery disease	I73, I73.8, I73.9, and I74
Heart failure	I50, I11.0, I13.0, and I13.2
<b>Procedures</b>	
Coronary revascularisation	Z95.5, Z95.8, Z95.9
Revascularisation of other vascular territories	I97.8, I97.9